Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

PharmaCielo Signs Sales Agreement With Brazilian Phyto-Therapeutic Company

Author: Vuk Zdinjak | July 28, 2022 09:11am

PharmaCielo Ltd. (OTCQX:PCLOF) (TSXV:PCLO) , the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., entered into a supply agreement with one of the largest phyto-therapeutic companies in the Brazilian market. The customer has an extensive distribution network across Latin America, and is also a certified B-Corp, reflecting its commitment to a transparent business model that measures social and environmental impacts.

PharmaCielo will be registered with Anvisa as the sole supplier to the customer for this product, and under the agreement, PharmaCielo will ship significant quarterly volumes of a proprietary CBD derivative formulation to the Customer, which will be utilized in the production of novel herbal medicines to be distributed across Latin America. The company expects to begin shipping during Q1 2023.

Management Changes

PharmaCielo has appointed Ian D. Atacan to its board of directors. Atacan has been the company's CFO since June 7, 2021.

PharmaCielo has appointed Dr. Decio Rabelo de Castro Filho as chief medical officer of the company, to advance the company's visibility within physician communities and with pharmaceutical organizations in Latin America, Europe and other key markets globally.

Dr. de Castro Filho is a medical doctor with over 20 years of experience in occupational medicine and marketing. During the course of his career, Dr. de Castro Filho has also acted as an expert medical witness for several large Brazilian companies. Dr. de Castro Filho is a graduate of the medical program at Pontifical Catholic University of Campinas and has a master's degree in Marketing from Escola Superior de Propaganda e Marketing ESPM in São Paulo. He holds a degree in cannabinoid medicine from the Wecann Academia school.

Photo: Benzinga; Sources:  geralt, lindsayfox via Pixabay

Related News

PharmaCielo Ships CBD Full Spectrum Oil To A Brazilian Pharmaceutical Compan

PharmaCielo Q1 Revenue Increases 77.92% YoY, Discusses International Market

PharmaCielo Enters Spanish Market With Initial Shipment Of 300Kg Of CBD Full Spectrum Oil To Extractions Solutions

 

Posted In: PCLOF TSXV:PCLO